Hardy Kiwifruit Extract Modulates Th1/Th2 Cytokine Balance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic diseases, such as anaphylaxis, asthma, and atopic dermatitis, primarily focus on symptomatic relief and do not effectively address the underlying immunological mechanisms, particularly the imbalance between Th2 and Th1 cytokines and IgE levels, leading to incomplete cure and ongoing inflammation.
Innovation Solution
A pharmaceutical composition comprising an extract of hardy kiwifruit, which inhibits histamine release from mast cells, increases Th1 cytokines, and reduces Th2 cytokines and IgE levels, thereby providing a comprehensive approach to treating and preventing allergic and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional drugs (anti-histamines, steroidal anti-inflammatory drugs, leukotriene antagonists) are used for treatment, then symptomatic relief is achieved, but the fundamental immunological imbalance (Th2 cytokine dominance, IgE production) is not addressed
Solution Approach 1:
The patent introduces a natural compound (flavonoid or its derivative) as an intermediary substance that mediates between the immune system and the allergic response. This compound specifically targets the immunological imbalance by modulating Th2 cytokine production and IgE synthesis, acting as a bridge to address the root cause rather than just symptoms
Solution Approach 2:
The patent replaces conventional symptomatic treatment mechanisms with a biological modulation mechanism. Instead of using anti-histamines to block histamine receptors or corticosteroids to suppress inflammation broadly, the invention uses a natural compound that specifically regulates the immunological pathway (Th2 cytokine-IgE-mast cell axis) to achieve fundamental treatment
2Reliability
If immunotherapy is performed to address fundamental immunological mechanisms, then Th2 cytokine dominance and IgE production are reduced, but the treatment process is complex and time-consuming
Solution Approach 1:
The patent extracts the essential active component (flavonoid or its derivative) from natural sources and isolates its specific immunomodulatory function. This extracted compound directly targets the Th2 cytokine-IgE pathway, simplifying the complex immunotherapy process into a single actionable substance that can be administered without the complexity of traditional immunotherapy protocols
Solution Approach 2:
The patent changes the parameter of treatment delivery by using a natural compound with specific biochemical properties (flavonoid structure) that naturally interacts with the immune system. This changes the treatment from a complex procedural intervention to a simpler pharmacological intervention that modifies immune response parameters (Th2 cytokine levels, IgE production) through natural biochemical pathways
3Object-affected harmful factors
If natural compounds are used as treatment, then non-toxic and comprehensive treatment is achieved, but the specific mechanism of action on Th2/Th1 cytokine balance needs to be established
Solution Approach 1:
The patent establishes a feedback mechanism by measuring specific immunological parameters (Th2 cytokine levels, IgE production, mast cell degranulation) to verify the compound's effect. This feedback loop confirms that the natural compound is achieving the desired immunomodulatory effect by reducing Th2 dominance and restoring Th1/Th2 balance, making the mechanism detectable and measurable
Data Source
AI summary
The present invention provides a pharmaceutical composition comprising the extract of hardy kiwifruit as an active ingredient in an effective amount to treat and prevent allergic disease and non-allergic inflammatory disease by reducing inflammation action, by inhibiting histamine release from mast cell, and by increasing the level of Th1 cytokines, IgG2a in serum and reducing the level of Th2 cytokines and IgE in serum. The present invention also provides a use of above extract for the preparation of pharmaceutical composition. The present invention also provides a health food or food additives, a cosmetic composition, a feed or feed additives comprising above extract for prevention or alleviation of allergic disease and non-allergic inflammatory disease by reducing inflammation action, by inhibiting histamine release from mast cell, and by increasing the level of Th1 cytokines, IgG2a in serum, and reducing the level of Th2 cytokines and IgE in serum.